drugset
drugset / Trial / NCT00029900

ADI-PEG in Patients With Metastatic Melanoma

NCT00029900 ↗

Phase 1 Completed 15 enrolled FDA Office of Orphan Products Development
Non-randomizedOpen-labelTreatment

Summary

This is a study to determine the safety and toxicity of increasing doses of arginine deiminase combined to polyethylene glycol (ADI-PEG) in patients with nonresectable metastatic melanoma.

Timeline

Start
2001-09
Primary completion
—
Completion
2003-08

Drugs

EvaluationDrugModalityDoseRoute
Subject ADI-SS PEG Protein / enzyme biologic — Intramuscular

Indications

melanoma metastatic neoplasm